Betrixaban

CAS: 330942-05-7

Ref. TM-T4341

Produktinformation

• Name: Betrixaban
• Synonyme: PRT054021, Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-, Bevyxxa, N-(5-Chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxybenzamide, Prt 054021
• CAS: 330942-05-7

Beschreibung

Betrixaban (PRT054021) is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4].

• Marke: Targetmol

Chemische Eigenschaften

• Molekulargewicht: 451.91
• Formel: C₂₃H₂₂ClN₅O₃
• Reinheit: 99.35%
• Farbe/Form: Solid